Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms

Cancer

Volumn 113, Issue 1, 2008, Pages 126-134

  Cho, Clifford S ^a   Labow, Daniel M ^b,c   Tang, Laura ^b   Klimstra, David S ^b   Loeffler, Agnes G ^a   Leverson, Glen E ^a   Fong, Yuman ^b   Jarnagin, William R ^b   D'Angelica, Michael I ^b   Weber, Sharon M ^a   Blumgart, Leslie H ^b   DeMatteo, Ronald P ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Grade; Liver; Metastases; Neuroendocrine; Pathology; Surgery

Indexed keywords

OCTREOTIDE;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER RESECTION; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; TUMOR NECROSIS;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 47149094491     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23523     Document Type: Article

References (21)

1. Moertel CG. Karnofsky memorial lecture. An Odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502-1522.
2. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-445.
3. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88-92.
4. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-783.
5. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091-1096.
6. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36-42.
7. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37.
8. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci. 2004;1014:13-27.
9. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic neuroendocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633-2642.
10. Cunningham JD, Fong Y, Shriver C, Melendez J, Marx WL, Blumgart LH. One hundred consecutive hepatic resections. Blood loss, transfusion, and operative technique. Arch Surg. 1994;129:1050-1056.
11. Martin RC, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg. 2002;194: 568-577.
12. Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery. 1988;104:1011-1017.
13. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302-309.
14. di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials Medical Oncology Group. Cancer. 1996;77:402-408.
15. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104: 1590-1602.
16. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572-581.
17. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934-944.
18. Nassar H, Albores-Saavedra J, Klimstra DS. High-grade neuroendocrine carcinoma of the ampulla of Vater: a clinicopathologic and immunohistochemical analysis of 14 cases. Am J Surg Pathol. 2005;29:588-594.
19. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677-682.
20. Chung MH, Pisegna J, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery. 2001;130:954-962.
21. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000-1004.